About this trial
Cutaneous melanoma frequently develops cutaneous and subcutaneous metastases, which may cause significant morbidity and negatively affect quality of life. Electrochemotherapy (ECT) is an established local treatment modality for cutaneous and subcutaneous tumor lesions that combines the administration of cytotoxic drugs with the application of electric pulses to increase drug uptake into tumor cells.
In addition to its direct cytotoxic effects, electrochemotherapy may induce changes in the tumor microenvironment, including immune cell infiltration, vascular alterations, and other biological responses that could influence tumor control.
The aim of this study is to evaluate changes in the tumor microenvironment of cutaneous and subcutaneous melanoma metastases following electrochemotherapy with either intravenous bleomycin or intratumoral cisplatin. Tumor tissue samples collected before and after treatment will be analyzed to characterize microenvironmental changes and to compare treated and untreated lesions.
The results of this study may improve understanding of biological effects of electrochemotherapy in melanoma metastases and support further development of treatment strategies.
Eligibility criteria
Qualifiers
Adults aged 18 years or older
Histologically confirmed cutaneous melanoma
Presence of cutaneous and/or subcutaneous metastases eligible for electrochemotherapy
Candidate for electrochemotherapy with intravenous bleomycin or intratumoral cisplatin according to standard clinical practice
Disqualifiers
Contraindication to electrochemotherapy or study drugs (bleomycin or cisplatin)
Pregnancy or breastfeeding
Severe comorbidities preventing electrochemotherapy
Inability to comply with study procedures
Trial design
Treatments tested in this trial
- Electrochemotherapy